Show simple item record

dc.contributor.authorGelderblom, H
dc.contributor.authorBlay, J
dc.contributor.authorSeddon, B
dc.contributor.authorLeahy, Michael G
dc.contributor.authorRay-Coquard, I
dc.contributor.authorSleijfer, S
dc.contributor.authorKerst, J M
dc.contributor.authorRutkowski, P
dc.contributor.authorBauer, S
dc.contributor.authorOuali, M
dc.contributor.authorMarreaud, S
dc.contributor.authorvan der Straaten, R
dc.contributor.authorGuchelaar, H
dc.contributor.authorWeitman, S
dc.contributor.authorHogendoorn, P
dc.contributor.authorHohenberger, P
dc.date.accessioned2014-03-05T10:41:13Z
dc.date.available2014-03-05T10:41:13Z
dc.date.issued2014-01
dc.identifier.citationBrostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. 2014, 50 (2):388-96 Eur J Canceren
dc.identifier.issn1879-0852
dc.identifier.pmid24215845
dc.identifier.doi10.1016/j.ejca.2013.10.002
dc.identifier.urihttp://hdl.handle.net/10541/313657
dc.description.abstractBrostallicin is a DNA minor groove binder that has shown activity in patients with soft tissue sarcoma (STS) failing first-line therapy. The present study assessed the safety and efficacy of first-line brostallicin in patients with advanced or metastatic STS >60 years or not fit enough to receive combination chemotherapy. A prospective explorative pharmacogenetic analysis was undertaken in parallel.
dc.language.isoenen
dc.rightsArchived with thanks to European journal of cancer (Oxford, England : 1990)en
dc.titleBrostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.en
dc.typeArticleen
dc.identifier.journalEuropean Journal of Canceren
html.description.abstractBrostallicin is a DNA minor groove binder that has shown activity in patients with soft tissue sarcoma (STS) failing first-line therapy. The present study assessed the safety and efficacy of first-line brostallicin in patients with advanced or metastatic STS >60 years or not fit enough to receive combination chemotherapy. A prospective explorative pharmacogenetic analysis was undertaken in parallel.


Files in this item

This item appears in the following Collection(s)

Show simple item record